Business
Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022
MARLBOROUGH, Mass., March 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"MARLBOROUGH, Mass., March 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it is scheduled to present new preclinical data on PH-894, Phio's self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4), in an in-person poster session at the AACR Annual Meeting 2022, which is being held in New Orleans, Louisiana, from April 8-13, 2022. \nLogo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg \nPresentation Details are as follows:\nTitle: \nLocal administration of BRD4-targeting self-delivering RNAi (PH-894) provides abscopal efficacy toward untreated distal tumors and potentiates the efficacy of systemic anti-PD-1 antibody therapy\nAuthor: \nBenjamin Cuiffo, et al.\nAbstract Number: \n4237\nSession Date and Time: \nWednesday Apr 13, 2022 9:00 AM - 12:30 PM\nLocation: \nNew Orleans Convention Center, Exhibit Halls D-H, Poster Section 38\nThe poster presentation will be accessible in person and virtually and will also be made available on the \"Investors – Events and Presentations\" section of the Company's website (click here).\nAbout Phio Pharmaceuticals Corp.\nPhio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.\nForward Looking Statements\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as \"intends,\" \"believes,\" \"anticipates,\" \"indicates,\" \"plans,\" \"expects,\" \"suggest...